Four myeloma experts review the data presented at the 2026 International Myeloma Society Annual Meeting from the Phase 2 CARTITUDE-2 Cohort A study. The moderator and the panelists discuss the data alongside the rest of the CARTITUDE program, talk through patient selection, treatment sequencing, collaboration with the community referring center, long-term follow-up, and then work through a clinical scenario of a patient at first relapse who may be a candidate for referral.
A hematopathologist and 2 leukemia specialists discuss menin inhibition inNPM1-mutated and KMT2A-rearranged AML. They walk through thebiologic rationale for menin inhibition; molecular testing; and distinguish between FDA-approved menin inhibitors’ safety, administration, and management. The program finishes with 2 clinical scenarios covering agent selection, shared care, and transplant.
Three myeloma specialists discuss delivering belantamab mafodotinwith bortezomib and dexamethasone in relapsed or refractory multiple myeloma, covering patient selection, DREAMM-7 data,REMS requirements, oncology and eye care coordination, ocular monitoring, dose modification, treatment continuity, and 2 clinical scenarios.
Estelamari Rodriguez, MD, MPH, of Sylvester Comprehensive Cancer Center, Matthew Gumbleton, MD, PhD, of Huntsman Cancer Institute, and Siddhartha Devarakonda, MD, of Providence Swedish Cancer Institute discuss first-line treatment selection in EGFR-mutated advanced non–small cell lung cancer, covering mature survival data from MARIPOSA and FLAURA2, high-risk features including brain metastases and TP53 co-mutation, and how route and frequency of administration shape treatment delivery in community practice.
This CancerNetwork® Around the Practice program examines evolving treatment strategies for hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2− mBC) after progression on first-line CDK4/6 inhibitor plus endocrine therapy. Dr. Seth Wander leads a multidisciplinary discussion with Dr. Erica Mayer, Dr. Kathryn Post, and Dr. Jennifer Hutchinson on how clinical characteristics, patient preferences, and biomarker testing inform second-line treatment selection. The experts discuss the importance of reassessing ESR1 and PI3K/AKT/mTOR pathway alterations at progression and review therapeutic strategies for biomarker-negative, ESR1-mutant, and PIK3CA-altered disease. The program highlights the evolving role of oral SERDs and targeted pathway inhibitors, including capivasertib and gedatolisib, as well as the place of antibody-drug conjugates and chemotherapy in later-line treatment. The panel also reviews emerging treatment strategies, including molecularly guided intervention before clinical progression. Throughout the discussion, emphasis is placed on balancing efficacy, toxicity, treatment burden, adherence, and patient goals through multidisciplinary, patient-centered care.
In this CancerNetwork® Around the Practice® program, Joshua K. Sabari, MD, is joined by a medical oncologist, an advanced practice provider, and an oncology pharmacist to work through the management of HER2/ERBB2-mutant non–small cell lung cancer (NSCLC) in the community setting. The panelists separate HER2 amplification, overexpression, and activating mutations; identify where next-generation sequencing workflows fail to surface ERBB2 exon 20 insertions; and review first-line efficacy and safety data for zongertinib and sevabertinib alongside chemoimmunotherapy. They also address central nervous system metastases, the first 30 days on oral targeted therapy, prior authorization and refill adherence, and multidisciplinary adverse event triage. Two patient cases anchor the discussion: a newly diagnosed patient balancing full-time work against treatment logistics, and a patient with asymptomatic brain metastases who questions whether stereotactic radiosurgery is necessary if systemic therapy can address both sites of disease.
Panelists discuss nursing management of toxicity, adherence, and long-term care across first-line regimens for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC), from baseline assessment and patient and caregiver education through prophylactic skin care, telephone triage, interstitial lung disease workup, grading-based dose decisions, diarrhea and nutrition support, and infusion-related reaction and clot prevention. Two patient scenarios anchor the later portion, covering treatment intensification beyond single-agent therapy and long-term oral adherence, alongside specialty pharmacy access, financial toxicity, consolidation after chemoradiation, central nervous system monitoring and steroid tapers, survivorship needs, and building nurse-driven programs in community practice.
Three leading women in Multiple Myeloma discuss where ciltacabtagene autoleucel belongs among BCMA-directed options after CARTITUDE-1 and CARTITUDE-4, and how community practices and CAR T centers coordinate ciltacabtagene autoleucel therapy, including recognition and management of delayed neurotoxicity, infection prevention, and identification of patients who should be referred to a CAR-T center.
Three breast medical oncologists examine how aromatase inhibitor therapy drives ESR1 mutation emergence in hormone receptor-positive, HER2-negative metastatic breast cancer, and discuss how phase 3 SERENA-6 data inform monitoring, patient communication,and treatment in practice.
First-line management of EGFR-mutated advanced non-small cell lung
cancer has moved from a single-agent standard to several guideline-preferred regimens, each
with distinct efficacy, safety, and administration profiles. In this Around the Practice program, a
panel of thoracic oncology experts works through how to select and sequence frontline therapy
in this evolving landscape. The discussion begins with the molecular testing foundation,
including complementary tissue and plasma profiling and the workflows that ensure timely,
comprehensive results. Faculty then compare the preferred regimens, single-agent and
combination approaches alike, weighing efficacy against tolerability, administration burden, and
quality of life. Through patient cases, the panel illustrates individualized, preference-sensitive
decision-making across higher-risk and comorbidity-driven scenarios, along with practical
toxicity prevention and monitoring. The program closes on resistance, molecular retesting at
progression, sequencing of subsequent therapy, and real-world implementation, offering
community and academic teams an applied framework for optimizing outcomes in
EGFR-mutated NSCLC.
Dr. Ami Shah from Northwestern University moderated a comprehensive discussion with Drs. Megan Kruse and Ruta Rao on the evolving treatment landscape for patients with HER2-positive breast cancer. The program focused on interpreting emerging data from pivotal Phase 3 trials of HER2-directed antibody-drug conjugates across neoadjuvant, adjuvant, and metastatic settings.
Key topics included the DESTINY-Breast09, -11, and -05 trials demonstrating trastuzumab deruxtecan's (T-DXd) efficacy combined with pertuzumab in first-line metastatic disease (median PFS 40.7 vs 26.9 months), neoadjuvant therapy (67% vs 56% pathologic complete response), and adjuvant treatment for residual disease (92% vs 84% three-year invasive disease-free survival).
The discussion emphasized deep response assessment, with complete responses occurring by 8 months and deepest responses by 24 months on therapy. CNS disease management was highlighted as a critical consideration, with T-DXd's proven intracranial activity influencing treatment selection. Practical aspects included interstitial lung disease monitoring with high-resolution CT scans, proactive nausea management with multi-agent antiemetics including olanzapine, and dose reduction strategies maintaining efficacy while improving tolerability.
Dr. Neil Iyengar from Winship Cancer Institute moderated a comprehensive discussion with Dr. Sara Nunnery, Dr. Sarah Sunshine, and Ms. Debbi-Ann Davidson on evolving treatment strategies for hormone receptor-positive, HER2-negative metastatic breast cancer and triple-negative breast cancer.
The program focused on antibody-drug conjugate evidence from recent trials including TROPION-Breast01, TROPION-Breast02, ASCENT-03, and ASCENT-07. Key topics included treatment sequencing strategies: trastuzumab deruxtecan for HER2-low/ultra-low patients, followed by TROP2-targeted ADCs (datopotamab deruxtecan and sacituzumab govitecan) after chemotherapy progression.
Practical management emphasized multidisciplinary care coordination, particularly for ocular toxicity monitoring with datopotamab deruxtecan requiring baseline eye exams and every-3-cycle ophthalmologic assessments. Nursing perspectives highlighted proactive patient education for toxicity prevention, including artificial tears prophylaxis and stomatitis prevention.
Clinical scenarios demonstrated real-world decision-making considering patient comorbidities, quality of life priorities, and treatment tolerability. The discussion underscored the importance of maximizing endocrine therapy before cytotoxic treatments and individualizing ADC selection based on efficacy data, toxicity profiles, and patient-specific factors in both disease settings.
In this CancerNetwork® Around the Practice series, moderator Gaurav Singh, MPH, FACMS, leads a multidisciplinary panel in a comprehensive discussion of advanced cutaneous squamous cell carcinoma (cSCC). Experts Soo Park, MD, Jonathan Schoenfeld, MD, Vernon Sondak, MD, and Jonathan Zager, MD, explore the clinical features that define high-risk disease and guide patient stratification; the evidence supporting cemiplimab across the advanced, neoadjuvant, and adjuvant settings; and the critical role of multidisciplinary care in optimizing outcomes. Through 2 patient case discussions, the panel addresses real-world treatment decision-making, toxicity management, and goals-of-care conversations for complex patients, including those with immunosuppression and hematologic malignancies. The series concludes with a look at emerging biomarkers, combination strategies, and future directions in the field.
In this CancerNetwork® Around the Practice series, Omid Hamid, MD, of Cedars-Sinai The Angeles Clinic and Research Institute, will lead a multidisciplinary panel in a comprehensive discussion of advanced cutaneous squamous cell carcinoma (cSCC). The experts will examine the epidemiology and clinical challenges of advanced cSCC, including disease progression, patient comorbidities, and the transition from localized to unresectable or metastatic disease. The panel will review clinical evidence for immune checkpoint inhibitors, including cemiplimab, pembrolizumab, and cosibelimab, covering efficacy, safety profiles, and real-world patient selection. Through two patient-based
This program will focus on the evolving role of adjuvant targeted therapy in early-stage EGFR-mutated non–small cell lung cancer, with an emphasis on translating clinical trial evidence into real-world practice.
They will discuss the importance of timely molecular testing, multidisciplinary coordination, and appropriate treatment selection in the curative-intent setting. We will also explore practical considerations related to long-term treatment adherence and patient counseling, and review patient case scenarios to illustrate how these decisions are made in everyday clinical practice.
They will also discuss the evolving role of neoadjuvant targeted strategies and the importance of early biomarker testing in guiding multidisciplinary decision-making.
This discussion reviews the latest clinical evidence guiding first-line treatment selection for patients with EGFR-mutated metastatic non–small cell lung cancer (NSCLC). Experts examine key data on overall survival outcomes, central nervous system (CNS) activity, safety profiles, and how current therapies align with evolving clinical guideline recommendations.
The conversation also highlights practical considerations for integrating modern EGFR-targeted therapies into everyday clinical practice, including treatment administration methods, dosing schedules, strategies for managing adverse events, and the role of dose modifications while maintaining therapeutic efficacy.
Finally, the discussion explores approaches to individualizing treatment for patients with EGFR-mutated metastatic NSCLC, with particular attention to managing brain metastases, minimizing treatment burden, and achieving durable, well-tolerated long-term disease control.
Panelists discuss how CAR T-cell therapy in relapsed/refractory multiple myeloma is supported by strong trial and real-world outcomes, and how optimizing patient selection and sequencing—while proactively addressing referral, logistical, toxicity, and insurance/financial barriers—can expand timely access and improve care delivery.
This program, recorded live from the San Antonio Breast Cancer Symposium, convened leading breast medical oncologists. Dr. McArthur, Dr. Gradishar, Dr. Rao, Dr. Sammons, and Dr. Traina, to discuss the latest advances in the treatment of advanced or metastatic breast cancer. The panel covered evolving genomic testing strategies, the integration of new targeted therapies, interpretation of clinical trial data, and implications for clinical practice. Key trials and recent FDA approvals were highlighted, with insights into optimizing sequencing and combination of therapies for hormone receptor-positive, HER2-positive, and triple negative breast cancer. The conversation emphasized the growing complexity and promise in the field, as well as the challenges in personalizing care for diverse patient populations.
This Around the Practice discussion series, BCMA Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: Real-World Integration and Patient-Centered Management, brings together leading experts Sundar Jagannath, MBBS, Icahn School of Medicine at Mount Sinai Hospital; Ajay Nooka, MD, MPH, FACP and Nisha Joseph, MD (Winship Cancer Institute of Emory University); Mohan Krishnamachary, MD (Suburban Hematology Oncology Associates); and Donna Catamero, MSN, ANP-BC, OCN, CBCN (Icahn School of Medicine at Mount Sinai Hospital), for a focused conversation recorded at ASH 2025. Through deep dives into pivotal data, agent comparisons, and a complex real-world case, the panel examines how BCMA bispecific antibodies—particularly linvoseltamab, teclistamab, and elranatamab—are being integrated alongside CAR T-cell therapy, with attention to toxicity mitigation, infection prophylaxis, and duration of therapy. The dialogue emphasizes practical strategies for transitioning care from academic to community settings, optimizing outpatient management, and ensuring that high-risk, heavily pretreated patients can safely access these potentially life-prolonging—and, in some cases, potentially curative—therapies.
This program focuses on optimizing the use of oral hypomethylating agents (HMAs) in myeloid malignancies, primarily high-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). A multidisciplinary panel of hematologists, transplant specialists, and an oncology nurse practitioner discusses real-world cases involving TP53-mutated MDS and proliferative CMML, both complicated by cytopenias, comorbidities, logistical challenges, and patient preferences. Panelists review evidence supporting oral decitabine/cedazuridine as a practical and clinically effective therapy comparable to intravenous HMAs. They also discuss transplant candidacy, timing, and the emerging role of combination therapies such as venetoclax with oral HMAs. Across the program, speakers emphasize individualized patient-centered care, balancing disease control with quality of life, treatment burden, telemedicine integration, and realistic expectations. The experts conclude that oral HMA therapy will lead to broader community-based treatment, greater patient autonomy, and future expansion of combination regimens and clinical trials.
This program provides an in-depth discussion on the evolving treatment strategies for patients with EGFR-mutant metastatic non-small cell lung cancer (mNSCLC), emphasizing the role of combination therapies to improve survival outcomes. Experts review recent clinical trial data, particularly focusing on central nervous system (CNS)-active regimens such as amivantamab plus lazertinib and osimertinib combinations. They highlight patient selection, emphasizing high-risk populations with CNS metastases or high tumor burden, and discuss the clinical rationale for early, aggressive therapy versus de-escalation approaches. Safety, tolerability, and patient-centered care are emphasized, including management of adverse events and considerations for quality of life. The program also addresses long-term treatment planning, highlighting the “marathon” nature of therapy and the importance of optimizing first-line interventions to maximize overall survival. Finally, emerging innovations, including subcutaneous formulations of amivantamab, are explored as ways to improve convenience and adherence, demonstrating the potential for both efficacy and improved patient experience in routine clinical practice.
This Around the Practice program brings together a multidisciplinary panel to examine evolving perioperative strategies for resectable gastroesophageal and gastric cancers, with a particular focus on integrating systemic therapy, immunotherapy, and surgical planning. Panelists review emerging data from key studies, including the DFLOT regimen evaluated in the MATTERHORN trial, and discuss how these findings may influence real world care once regulatory decisions are finalized. Throughout the program, the experts highlight the importance of accurate staging, appropriate patient selection, and careful assessment of treatment tolerance when approaching complex early stage disease. The discussion incorporates practical considerations faced in both academic and community settings, including nutrition support, feeding access, performance status preservation, germline testing, and the coordination required for patients living at a distance from major centers. Two detailed patient cases illustrate decision making around PD L1 status, locally advanced tumor biology, and multidisciplinary management. The program concludes with reflections on future directions in biomarker driven perioperative therapy and the expanding role of collaborative care teams.
This Around the Practice discussion series, Evolving Strategies in EGFR-Mutated NSCLC: Optimizing CNS Control and Managing Treatment-Related Toxicities, brings together leading experts Misako Nagasaka, MD, PhD; Luis Raez, MD; Edgardo Santos, MD, FACP, FASCO; and Jun Zhang, MD, PhD, to explore the newest data and clinical approaches in treating EGFR-mutated non–small cell lung cancer. Through real-world cases, the panel examines how dual EGFR-MET pathway inhibition, exemplified by amivantamab plus lazertinib, is reshaping frontline therapy, central nervous system management, and sequencing beyond progression. The dialogue emphasizes proactive toxicity prevention, multidisciplinary care, and individualized strategies to improve patient outcomes, long-term survival, and quality of life
Panelists discuss how bispecific antibody therapies are revolutionizing multiple myeloma treatment by providing highly effective, accessible options for heavily pretreated patients while addressing key implementation challenges including patient selection, sequencing strategies, safety management protocols, and the transition from academic centers to community-based care delivery.
Jan Drappatz MD; Elizabeth Maher, MD, PhD; Alexandra M. Miller, MD, PhD; and David Reardon, MD discuss how the 2021 WHO classification emphasizing molecular markers like IDH mutations has transformed glioma treatment from a histology-based approach to personalized therapy, with IDH inhibitors offering new first-line options that can defer radiation and chemotherapy while maintaining quality of life for patients with IDH-mutant gliomas.
Samuel Rosner, MD, discusses how the treatment landscape for EGFR-mutated non-small cell lung cancer has evolved from first-generation targeted therapies to osimertinib as the current standard of care, while exploring emerging options like fourth-generation TKIs, antibody-drug conjugates, and bispecific therapies to overcome resistance mechanisms.
Ajai Chari, MD; Ajay Nooka, MD, MPH, FACP; Muhamed Baljevic, MD; Gurbakhash Kaur, MD; and Anupama Kumar, MD, discuss how recent advances in multiple myeloma (MM) treatment, including quadruplet therapy regimens, CAR T-cell therapies in earlier lines, and emerging bispecific antibodies and trispecific agents, are transforming the treatment landscape with the potential to cure rather than just manage the disease, while addressing optimal sequencing strategies and management of adverse events across newly diagnosed and relapsed/refractory (R/R) settings.
Panelists discuss the evolving role of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM), highlighting its transformative impact on patient outcomes across diverse real-world settings, the importance of individualized treatment decisions based on comparative efficacy and toxicity of available therapies, innovative approaches like bridging with bispecific antibodies, strategic sequencing with other B-cell maturation antigen–targeted agents, early integration in the treatment pathway, proactive management of neurotoxicity and infections, expanding access to high-risk populations, and the critical need for collaboration between specialized centers and community providers to optimize patient care and maximize durable responses.
Panelists highlighted evolving personalized treatment strategies in HER2-positive metastatic breast cancer—spanning maintenance therapy innovations, frontline and later-line sequencing with agents like trastuzumab deruxtecan and tucatinib, management of CNS metastases and toxicities such as interstitial lung disease, and the critical role of multidisciplinary care and clinical trials in optimizing patient outcomes and quality of life throughout complex, prolonged disease courses.
Leslie Randall, MD; Marion E. Cole, MD; Asim Farooq, MD, and Mallorie Haba, FNP, discuss how antibody-drug conjugates are transforming treatment strategies in recurrent ovarian cancer by offering new options for patients with platinum-resistant disease, emphasizing molecular testing, treatment sequencing, side effect management—particularly ocular toxicities—and the importance of patient-centered care.
